title: Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
abstract: OBJECTIVE
  The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence.
  
  
  METHODS
  Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence.
  
  
  RESULTS
  Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos.
  
  
  CONCLUSIONS
  PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.
authors.affiliation: Sacro Cuore-Don Calabria Hospital of Negrar, Verona - Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bogina
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Lunardi
authors.forename: Francesca
authors.initials: F
authors.lastname: Coati
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Zamboni
authors.forename: Stefania
authors.initials: S
authors.lastname: Gori
authors.forename: Laura
authors.initials: L
authors.lastname: Bortesi
authors.forename: Marcella
authors.initials: M
authors.lastname: Marconi
authors.forename: Paola Agnese
authors.initials: PA
authors.lastname: Cassandrini
authors.forename: Monica
authors.initials: M
authors.lastname: Turazza
authors.forename: Laura
authors.initials: L
authors.lastname: Cortesi
authors.forename: Elisabetta
authors.initials: E
authors.lastname: DeMatteis
authors.forename: Guido
authors.initials: G
authors.lastname: Ficarra
authors.forename: Toni
authors.initials: T
authors.lastname: Ibrahim
authors.forename: Patrizia
authors.initials: P
authors.lastname: Serra
authors.forename: Laura
authors.initials: L
authors.lastname: Medri
authors.forename: Sara
authors.initials: S
authors.lastname: Giraudi
authors.forename: Matteo
authors.initials: M
authors.lastname: Lambertini
authors.forename: Franca
authors.initials: F
authors.lastname: Carli
authors.forename: Jennifer
authors.initials: J
authors.lastname: Foglietta
authors.forename: Angelo
authors.initials: A
authors.lastname: Sidoni
authors.forename: Martina
authors.initials: M
authors.lastname: Nunzi
authors.forename: Corrado
authors.initials: C
authors.lastname: Ficorella
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Diadema
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Mastro
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology*; D049109:Cell Proliferation; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007558:Italy; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000737:chemistry* / Q000473:pathology*; D009367:Neoplasm Staging; D016017:Odds Ratio; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human